Advertisement

Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET”

  • René Raavé
  • Gerwin Sandker
  • Pierre Adumeau
  • Christian Borch Jacobsen
  • Floriane Mangin
  • Michel Meyer
  • Mathieu Moreau
  • Claire Bernhard
  • Laurène Da Costa
  • Adrien Dubois
  • Victor Goncalves
  • Magnus Gustafsson
  • Mark Rijpkema
  • Otto Boerman
  • Jean-Claude ChambronEmail author
  • Sandra HeskampEmail author
  • Franck DenatEmail author
Open Access
Letter to the Editor
  • 98 Downloads
Part of the following topical collections:
  1. Radiopharmacy

Dear Sir,

Following the publication of our article entitled “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET” in EJNMMI [1], readers sent us some remarks and questions. In this letter, we would like to address these questions by providing additional information about our study.
  • DFOcyclo* is derived from DFO and not from DFO*. In DFO*, the trihydroxamate DFO is elongated with an extra hydroxamate group, exactly the same as present in DFO. In DFOcyclo*, the DFO is elongated with a cyclic hydroxamate group having a different linker length.

  • During the manuscript review process, DFO*-NCS was made commercially available at ABX (catalogue number 7272). Therefore, the following statement in the introduction “However, in the absence of an improved, clinically applicable chelator, there is room for more efficient [89Zr]Zr4+ chelators” is no more correct.

  • The stability assays were performed in PBS at pH 7.4.

  • The amounts of DFO and EDTA used for the challenge experiments were calculated based on the amount of chelators.

  • DFOcyclo* was used as a racemate in the experiments reported in the article.

  • The results depicted in Figs. 4c and 5a are based on two different sets of experiments. Initially the in vivo stability of [89Zr]Zr-DFOcyclo*-trastuzumab was compared with [89Zr]Zr-DFO-trastuzumab, of which the results are depicted in Fig. 4c. Once we observed an improved in vivo stability of [89Zr]Zr-DFOcyclo*-trastuzumab, a subsequent in vivo study was performed to investigate its stability compared with [89Zr]Zr-DFO*-trastuzumab as well (Fig. 5). Although aimed at similar experimental conditions, the use of a freshly thawed cell line and new mice could have caused heterogeneity between the two experiments (e.g., increased tumor growth rates which result in different interstitial pressures that could affect the %ID/g), which could explain the slight differences in tumor uptake, blood kinetics, and uptake in other organs.

Notes

Compliance with ethical standards

The authors declare that they have no conflict of interest. This article does not contain any studies with human participants.

Reference

  1. 1.
    Raavé R, Sandker G, Adumeau P, Jacobsen CB, Mangin F, Meyer M, et al. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET. Eur J Nucl Med Mol Imaging. 2019;46(9):1966–77.  https://doi.org/10.1007/s00259-019-04343-2.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • René Raavé
    • 1
  • Gerwin Sandker
    • 1
  • Pierre Adumeau
    • 2
  • Christian Borch Jacobsen
    • 3
  • Floriane Mangin
    • 2
  • Michel Meyer
    • 2
  • Mathieu Moreau
    • 2
  • Claire Bernhard
    • 2
  • Laurène Da Costa
    • 2
  • Adrien Dubois
    • 2
  • Victor Goncalves
    • 2
  • Magnus Gustafsson
    • 3
  • Mark Rijpkema
    • 1
  • Otto Boerman
    • 1
  • Jean-Claude Chambron
    • 2
    • 4
    Email author
  • Sandra Heskamp
    • 1
    Email author
  • Franck Denat
    • 2
    Email author
  1. 1.Department of Radiology and Nuclear MedicineRadboud Institute for Molecular Life Sciences, Radboud UMCNijmegenThe Netherlands
  2. 2.Institut de Chimie Moléculaire de l’Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-ComtéDijon CedexFrance
  3. 3.Global Research TechnologiesNovo Nordisk A/SMåløvDenmark
  4. 4.Institut de Chimie de Strasbourg, UMR 7177, CNRS, Université de StrasbourgStrasbourg CedexFrance

Personalised recommendations